Retour sur lavenir.net
   ELIA GROUP 140.000 € (+1,67 %)     D'IETEREN GROUP 180.400 € (+0,56 %)     NYXOAH 1.700 € (+11,26 %)     AB INBEV 72.440 € (+1,86 %)     QRF(SUB)C15 0.035 € (+18,24 %)     ARGENX SE 830.800 € (+0,68 %)     AZELIS GROUP 9.885 € (+2,17 %)     COLRUYT 36.300 € (-0,82 %)     WDP 22.300 € (-0,54 %)     TITAN S.A. 52.000 € (+0,68 %)     SYENSQO 66.300 € (+1,22 %)     JENSEN-GROUP 84.800 € (+0,24 %)     AEDIFICA 69.700 € (+0,07 %)     ECONOCOM GROUP 1.485 € (-1,00 %)     EXMAR 11.000 € (-0,90 %)     NEXTENSA 46.320 € (+0,17 %)     INCLUSIO SA/NV 16.700 € (0,00 %)     VASTNED 29.500 € (-0,17 %)     ASCENCIO 51.900 € (-0,38 %)     CAMPINE 218.000 € (+0,46 %)     PROXIMUS 5.900 € (+0,43 %)     VIOHALCO 19.100 € (+1,06 %)     DEME GROUP 177.400 € (+2,19 %)     TUBIZE-FIN 224.400 € (-1,41 %)     WERELDHAVE BELGIUM 52.800 € (+0,38 %)     GIMV 45.950 € (+0,33 %)     CARE PROPERTY INV. 12.600 € (-1,25 %)     BREDERODE 104.600 € (+0,38 %)     SHURGARD 26.400 € (-0,38 %)     SOFINA 230.600 € (+0,61 %)     LOTUS BAKERIES 11 780.000 € (+1,38 %)     MELEXIS 78.550 € (+1,03 %)     UMICORE 21.360 € (+2,40 %)     TINC 11.260 € (-0,71 %)     CENERGY 23.000 € (+3,88 %)     EVS 27.500 € (+0,36 %)     HYLORIS 4.520 € (+0,89 %)     HOME INVEST BE. 19.200 € (-0,31 %)     BEKAERT 40.650 € (+2,52 %)     FLUXYS BELGIUM D 19.450 € (-1,52 %)     VAN DE VELDE 30.000 € (-0,33 %)     CMB.TECH 13.220 € (+2,48 %)     ONWARD MEDICAL 2.620 € (+0,77 %)     KINEPOLIS GROUP 37.000 € (+1,37 %)     CIE BOIS SAUVAGE 307.000 € (-0,65 %)     BARCO 8.520 € (+1,97 %)     WHAT'S COOKING GP 145.500 € (+3,56 %)     IBA 17.700 € (-0,11 %)     FAGRON 24.600 € (+0,82 %)     MONTEA 67.500 € (-0,59 %)     KBC 120.650 € (-0,86 %)     AGFA-GEVAERT 0.420 € (-0,24 %)     VGP 87.400 € (+0,34 %)     AGEAS 70.700 € (+0,43 %)     BPOST 1.670 € (+5,16 %)     SOLVAY 26.360 € (-0,60 %)     BANQUP GROUP 2.100 € (+0,96 %)     DECEUNINCK 2.275 € (+1,34 %)     TESSENDERLO 20.350 € (+0,25 %)     UCB 259.500 € (-1,93 %)  
   SANOFI 75.810 € (+0,74 %)     GETLINK SE 18.730 € (+1,19 %)     AKZO NOBEL 60.800 € (+1,00 %)     ASR NEDERLAND 66.560 € (-0,03 %)     CAPGEMINI 91.900 € (+0,37 %)     SHELL PLC 33.885 € (-0,24 %)     GENFIT 12.940 € (+22,31 %)     ASM INTERNATIONAL 975.600 € (+4,10 %)     TECHNIP ENERGIES 34.520 € (+3,42 %)     AIR LIQUIDE 180.300 € (+0,16 %)     AHOLD DEL 35.920 € (-0,66 %)     AB SCIENCE 0.773 € (+0,78 %)     ING GROEP N.V. 28.290 € (+0,21 %)     ALLFUNDS GROUP 8.575 € (+0,53 %)     MICHELIN 34.840 € (+0,35 %)     CROSSJECT 1.800 € (+0,67 %)     SBM OFFSHORE 30.680 € (+2,40 %)     DSM FIRMENICH AG 85.000 € (+2,29 %)     ACCOR 50.900 € (+0,35 %)     VALEO 13.275 € (+2,55 %)     VOLTALIA 7.200 € (+1,27 %)     AIR FRANCE -KLM 13.395 € (-0,37 %)     EUROPACORP 0.266 € (+9,92 %)     PHILIPS KON 24.690 € (+1,94 %)     ENGIE 27.730 € (+2,06 %)     LEGRAND 143.350 € (+1,59 %)     DNXCORP 17.750 € (-0,56 %)     UMG 18.995 € (-0,73 %)     ICADE 19.230 € (-0,83 %)     JCDECAUX 20.100 € (+1,11 %)     IPSEN 170.700 € (-0,23 %)     EUROCOMMERCIAL 27.450 € (0,00 %)     GECINA 72.800 € (-0,21 %)     UNILEVER 54.080 € (-0,39 %)     ADYEN 862.300 € (+0,85 %)     TKH GROUP 43.820 € (+2,19 %)     ABC ARBITRAGE 5.260 € (+0,57 %)     L'OREAL 382.450 € (-1,42 %)     STELLANTIS NV 4.930 € (-3,47 %)     AMG 33.080 € (+2,61 %)     SPIE 52.750 € (+5,50 %)     HERMES INTL 1 641.000 € (-0,36 %)     FUGRO 9.475 € (+0,74 %)     EXAIL TECHNOLOGIES 122.500 € (+0,99 %)     ARCADIS 33.780 € (+2,80 %)     S.E.B. 48.780 € (+0,58 %)     DASSAULT SYSTEMES 18.495 € (-0,94 %)     ORANGE 15.860 € (-0,06 %)     RENAULT 26.370 € (+1,66 %)     WOLTERS KLUWER 57.620 € (+0,07 %)     AIRBUS 206.150 € (+1,10 %)     FRANCAISE ENERGIE 42.100 € (+5,25 %)     VALNEVA 2.337 € (+4,10 %)     APERAM 45.500 € (+3,60 %)     THALES 238.200 € (-0,92 %)     ARCELORMITTAL SA 58.600 € (+5,89 %)     AEGON 7.672 € (+0,87 %)     NN GROUP 75.940 € (-0,24 %)     DRONE VOLT 0.389 € (+2,42 %)     BOLLORE 4.144 € (+0,83 %)  
News Réglementées
28/03/2023 14:00

Yunu Opens the Yunuverse, Increasing Trial Access for Patients and Solving Staffing Challenges for Cancer Centers, Pharma, and CRO Customers

All-new Yunuverse cloud community capabilities, now standard on the Yunu platform, make it possible for over 1,000 on-demand specialty-trained radiologists, technologists, and study staff to be invited and instantly participate in any of the 4,000 in-flight imaging clinical trials running on the system today. Cancer centers may now extend the reach of trial programs to satellite sites and imaging centers, improving patient access to sophisticated oncology trials.

CARY, NC / ACCESSWIRE / March 28, 2023 / Yunu, a clinical trials imaging assessment workflow and data management platform, has opened access to their new Yunuverse for collaboration among pharma sponsors, trial sites, clinical research organizations (CROs), and on-demand clinician groups to transform the way imaging-based trials are conducted. Yunu is a fast-growing VC-backed SaaS eClinical solution company that announced its Series A investment from First Analysis and exited from stealth in September of 2022. The company's technology has already been used in trials sponsored by over 400 pharma companies.

Yunu, Tuesday, March 28, 2023, Press release picture
Yunu is ensuring breakthrough therapies ​are accessible to everyone by delivering a new standard ​of clinical trial imaging workflow.

Yunu's success stems from a platform built with deep domain expertise in medical imaging and oncology research to deliver transparency and efficiency in every detail of the trial imaging workflow, from scheduling and billing to response criteria customization, performing imaging assessments, and audit readiness. Yunu's cloud-based system creates a much-needed collaboration environment across all trial stakeholders. Customers who already manage hundreds of trials within each site, including many of the nation's busiest NCI-designated Comprehensive Cancer Centers, can now effortlessly share imaging trial access, setup, staffing, and best practices with other sites and stakeholders within the application.

These new Yunu platform capabilities, called the Yunuverse, create an expansive network whereby Yunu stakeholders can invite new participants into their trials, including on-demand board-certified radiologists and other trial staffing resources, with no disruption or contracts, pre-set turn-around-times, and competitive 3rd party rates. Clinical research coordinators and administrative staff can choose local or offsite resources and make these selections on a trial-by-trial or individual study basis, with the freedom to adjust these preferences at any time.

As patient recruitment challenges and staffing shortages continue to plague clinical trials, the Yunuverse brings new avenues to extend trial access to new populations and augment trial teams, creating more diverse trials and accelerating the delivery of breakthrough therapies. Due to the difficulties imaging assessments present, trials have historically been limited to patient populations near the larger cancer centers that conduct them. As an alarming result, only 3% of US patients are enrolled in clinical trials where over 80% of Americans receive care. The Yunuverse is the first cloud collaboration tool to remove imaging barriers by decentralizing imaging assessments - patients and scanners can be in one location, with trial staff and physicians located anywhere.

"The Yunuverse addresses the vexing issues of patient access and staffing shortages in our nation's cancer centers and clinical trials programs. Current ways of working are insular, with each cancer center essentially on an island, being asked to run an increasing number of trials with a decreasing number of staff. Meanwhile, patients suffer from a lack of access because these trials are too difficult to run in community cancer centers and imaging centers," said Jeff Sorenson, Yunu Co-founder & CEO. He continued, "By facilitating collaboration across large and small sites, and by connecting CROs and pharma sponsors to sites in new ways, the Yunuverse is allowing institutions to rethink how they scale imaging operations in their clinical trials for the good of both patients and the research community."

The Yunuverse is being released in concert with two back-to-back industry events including the Outsourcing for Clinical Trials - Southeast conference in Raleigh, NC, on March 28th-29th and the Society for Clinical Research Sites - Global Oncology Site Solutions Summit in Austin, TX, on March 31st-April 1st.

Contact Information:

Lindsay Fleming
Chief Marketing Officer
press@yunu.io

SOURCE: Yunu

.

View source version on accesswire.com:
https://www.accesswire.com/745800/Yunu-Opens-the-Yunuverse-Increasing-Trial-Access-for-Patients-and-Solving-Staffing-Challenges-for-Cancer-Centers-Pharma-and-CRO-Customers

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière